How MPH was paid
$1.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Total |
|---|---|---|---|---|
| Paul A. Romness, MPHPresident and Chief Executive Officer | $480,000 | $242,168 | $1,220,000 | $1,942,168 |
| Robert G. Petit, Ph.D.Chief Medical and Scientific Officer | $420,000 | — | $610,000 | $1,030,000 |
| Christopher P. AcevedoChief Financial Officer | $36,000 | — | $244,000 | $280,000 |
What changed and why
- $1.94M$1.94 million was CEO total compensation in 2025, compared with $1.66 million in 2024.
- $242K$242,168 was the CEO’s 2025 incentive bonus for completing warrant inducement and exchange transactions.
- $1.22M$1.22 million was the CEO’s 2025 option award grant-date fair value.
- $610K$610,000 was Dr. Petit’s 2025 option award grant-date fair value.
- $244K$244,000 was Mr. Acevedo’s 2025 option award grant-date fair value.
- Options granted in October 2025 vest on October 21, 2026.
Other OS Therapies proxy statements
- 2025 proxy statement
Paul A. Romness, MPH paid $3.4M (+854% on the year).
Filed Aug 25, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.